Literature DB >> 12456444

The effects of intrathecal administration of an antagonist for prostaglandin E receptor subtype EP(1) on mechanical and thermal hyperalgesia in a rat model of postoperative pain.

Keiichi Omote1, Hiroki Yamamoto, Tomoyuki Kawamata, Yoshito Nakayama, Akiyoshi Namiki.   

Abstract

UNLABELLED: Despite substantial advances in understanding acute pain mechanisms and in the treatment of pain, postoperative pain, especially mechanically evoked pain (incident pain), is generally not effectively treated. Tissue injury and inflammation increase the release of prostaglandin E(2) in the spinal cord, contributing to the development of hyperalgesia. We designed the present study to determine whether the intrathecal administration of an antagonist for prostaglandin E(2) receptor subtype EP(1), ONO-8711, has an analgesic effect on incision-induced mechanical and thermal hyperalgesia. A 1-cm longitudinal skin incision was made in the plantar aspect of the rat foot. The withdrawal threshold to mechanical stimulation and the withdrawal latency to thermal stimulation applied adjacent to the wound of the hindpaw were investigated. Both mechanical and thermal hyperalgesia were observed at 2 h and 24 h after the incision had been made. ONO-8711 (50, 80, 100 micro g) or saline was administered intrathecally. ONO-8711 significantly increased the withdrawal thresholds to mechanical stimulation, but not to thermal stimulation, in a dose- and time-dependent manner. We conclude that EP(1) receptor-mediated sensitization of the spinal dorsal horn may contribute to the generation of mechanical, but not thermal, hyperalgesia and that an EP(1) receptor antagonist administered intrathecally is a potential analgesic for postoperative pain, especially mechanically evoked pain (incident pain). IMPLICATIONS: We examined the effects of an intrathecally administered selective EP(1) receptor antagonist on mechanical and thermal hyperalgesia in a postoperative pain model. The intrathecal EP(1) receptor antagonist inhibited the mechanical, but not thermal, hyperalgesia, indicating the potential for an EP(1) receptor antagonist to be used as an analgesic for postoperative pain, especially incident pain.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12456444     DOI: 10.1097/00000539-200212000-00044

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  7 in total

1.  Spinal inflammatory hyperalgesia is mediated by prostaglandin E receptors of the EP2 subtype.

Authors:  Heiko Reinold; Seifollah Ahmadi; Ulrike B Depner; Beate Layh; Cornelia Heindl; May Hamza; Andreas Pahl; Kay Brune; Shuh Narumiya; Ulrike Müller; Hanns Ulrich Zeilhofer
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

2.  Human microdose evaluation of the novel EP1 receptor antagonist GSK269984A.

Authors:  Thor Ostenfeld; Claire Beaumont; Jonathan Bullman; Maria Beaumont; Phillip Jeffrey
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

3.  Selective blockade of PGE2 EP1 receptor protects brain against experimental ischemia and excitotoxicity, and hippocampal slice cultures against oxygen-glucose deprivation.

Authors:  Abdullah Shafique Ahmad; Yun Tai Yun; Muzamil Ahmad; Takayuki Maruyama; Sylvain Doré
Journal:  Neurotox Res       Date:  2008-12       Impact factor: 3.911

4.  Pharmacological characterisation of a rat model of incisional pain.

Authors:  Garth T Whiteside; James Harrison; Jamie Boulet; Lilly Mark; Michelle Pearson; Susan Gottshall; Katharine Walker
Journal:  Br J Pharmacol       Date:  2003-11-03       Impact factor: 8.739

Review 5.  Prostanoid receptor antagonists: development strategies and therapeutic applications.

Authors:  R L Jones; M A Giembycz; D F Woodward
Journal:  Br J Pharmacol       Date:  2009-07-15       Impact factor: 8.739

6.  Prostanoid receptor EP1 and Cox-2 in injured human nerves and a rat model of nerve injury: a time-course study.

Authors:  Pascal F Durrenberger; Paul Facer; Maria A Casula; Yiangos Yiangou; Roy A Gray; Iain P Chessell; Nicola C Day; Sue D Collins; Sharon Bingham; Alex W Wilson; David Elliot; Rolfe Birch; Praveen Anand
Journal:  BMC Neurol       Date:  2006-01-04       Impact factor: 2.474

7.  TRPV1 antagonist attenuates postoperative hypersensitivity by central and peripheral mechanisms.

Authors:  Eva Uchytilova; Diana Spicarova; Jiri Palecek
Journal:  Mol Pain       Date:  2014-11-17       Impact factor: 3.395

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.